Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... and Elestrin™ (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma ...
2009 NOV 16 ... a Phase 3 trial of Menerba, its lead product candidate for the treatment of menopausal vasomotor symptoms. "The third quarter was an extremely productive quarter for ...
2009 NOV 2 ... through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development ...
2009 NOV 1 ... ( 40 nmol/min for 60 minutes) of 18 subjects, 6 +/- 4 years after transplantation. Vasomotor responses were measured in the infused artery and in a noninfused control artery in ...
2009 NOV 1 ... modulator DT56a (Femarelle), derived from soybean, has been shown to relieve menopausal vasomotor symptoms with no effect on sex steroid hormone levels or endometrial thickness. The ...
2009 NOV 1 ... The researchers concluded: "Treatment such as hormone therapy should be targeted to vasomotor symptoms, which are most strongly associated with menopause rather than to less specific ...
2009 NOV 23 ... with immediate HRT add-back showed less bone mineral density loss at 6 months and less vasomotor symptoms compared with those who had delayed HRT add-back treatment. Long-term follow up ...
2009 NOV 1 ... "The purpose of this study was to examine the associations of vasomotor symptoms with risk of all-cause, cardiovascular disease (CVD), and coronary heart ...
2009 NOV 17 ... rings and HCAECs were treated with different concentrations of LacCer for 24 hours. Vasomotor function was studied using a myograph tension system in response to thromboxane A2 ...
2009 NOV 16 ... rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons that maintain vasomotor tone located." "We also elucidated the molecular mechanisms that underlie ...
2009 NOV 2 ... 6%; P = 0.028), but there were no differences in endothelium-dependent and -independent vasomotor function or bradykinin-induced endothelial t-PA release (P > 0.05 for all). COPD is ...
2009 NOV 1 ... functioning. Other variables significantly related to HRQL across all domains included vasomotor symptoms, urine leakage, poor sleep, arthritis, depressed mood, perceived stress, and ...
2009 NOV 16 ... novel estrogen receptor beta agonist drug, Menerba, for the treatment of postmenopausal vasomotor symptoms. Current estrogen treatments are associated with a 12 to 24 fold increase in ...
2009 NOV 9 ... commonly, at elevated levels by increase in cardiac output and increased sympathetic vasomotor tone. Recovery of normal resting skeletal muscle tissue oxygen tension and skeletal ...
2009 NOV 23 ... cancer results in complications such as sexual dysfunction, poor quality of life, vasomotor symptoms and altered cognition. Since estrogen is associated with cardiovascular risks, ...
2009 NOV 23 ... effects." "Androgen-deprivation therapy (ADT) causes loss of libido, vasomotor flushing, anemia, and fatigue. More recently, ADT has been shown to accelerate bone ...
